When biomarkers are present at very low concentrations, conventional immunoassays may not provide the sensitivity needed to generate reliable, meaningful data. This can limit the ability to assess target engagement, monitor pharmacodynamic responses and track biomarker changes during treatment. Ultrasensitive immunoassays offer new opportunities to address these challenges. In this… Read More
Clinical trials continue to experience high attrition rates, with lack of efficacy being one of the leading causes of failure. However, in many cases, these failures do not reflect a lack of drug efficacy, but rather limitations in translational biomarker strategies and selection of disease-relevant pharmacodynamic (PD) biomarkers, suboptimal dose… Read More
Clinical trials continue to experience high attrition rates, with lack of efficacy being one of the leading causes of failure. However, in many cases, these failures do not reflect a lack of drug efficacy, but rather limitations in translational biomarker strategies and selection of disease-relevant pharmacodynamic (PD) biomarkers, suboptimal dose… Read More
When biomarkers are present at very low concentrations, conventional immunoassays may not provide the sensitivity needed to generate reliable, meaningful data. This can limit the ability to assess target engagement, monitor pharmacodynamic responses and track biomarker changes during treatment. Ultrasensitive immunoassays offer new opportunities to address these challenges. In this… Read More
When biomarkers are present at very low concentrations, conventional immunoassays may not provide the sensitivity needed to generate reliable, meaningful data. This can limit the ability to assess target engagement, monitor pharmacodynamic responses and track biomarker changes during treatment. Ultrasensitive immunoassays offer new opportunities to address these challenges. In this… Read More
Clinical trials continue to experience high attrition rates, with lack of efficacy being one of the leading causes of failure. However, in many cases, these failures do not reflect a lack of drug efficacy, but rather limitations in translational biomarker strategies and selection of disease-relevant pharmacodynamic (PD) biomarkers, suboptimal dose… Read More
Clinical trials continue to experience high attrition rates, with lack of efficacy being one of the leading causes of failure. However, in many cases, these failures do not reflect a lack of drug efficacy, but rather limitations in translational biomarker strategies and selection of disease-relevant pharmacodynamic (PD) biomarkers, suboptimal dose… Read More
Clinical trials continue to experience high attrition rates, with lack of efficacy being one of the leading causes of failure. However, in many cases, these failures do not reflect a lack of drug efficacy, but rather limitations in translational biomarker strategies and selection of disease-relevant pharmacodynamic (PD) biomarkers, suboptimal dose… Read More
Jack O’Meara CEO and Co-Founder of Aerska, compares the cardiovascular field to advances in neuroscience and how a preventative approach could be on the horizon for diseases such as Alzheimer’s. At Ochre Bio, the company I ran before Aerska, we spent years keeping human livers alive outside the body. Organs turned down for transplant, hooked up to… Read More
The Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator (DxA) and The Michael J. Fox Foundation (MJFF) have announced a new US$5 million partnership to accelerate the development of minimally invasive biomarkers for measuring pathologies associated with Parkinson’s and Alzheimer’s diseases. Isobel Coleman, Chief Executive Officer of the Alzheimer’s Drug Discovery… Read More
A new eBook is now available for DDW readers to download for free. In ‘The Full Guide to Precision Medicine’ sponsored by Evotec, readers can discover how biomarkers transform drug discovery and clinical development across the R&D continuum. What you will learn about: Understand biomarker types and their role in decision-making… Read More
Michael Eyres, Lead Scientist at the Medicines Discovery Catapult (MDC), explores how spatial epigenetics can accelerate biomarker drug discovery. Epigenetics, once seen… Read More
Dharminder Singh Chahal, Chief Executive Officer at SkylineDx, discusses the real-world applications of how SkylineDx bridges … Read More
Jesper Frank Bastlund, Senior Director in Biological and Translational Research, and Enchi Liu, Vice President, Head of Experimental Medicine at Lundbeck, examine how biomarkers can help advance… Read More
Genetic biomarkers could predict GLP-1 efficacy response, results show. Human omics company Ovation.io and precision medicine company PrecisionLife have released findings from the first phase of their collaboration, showing biomarkers can predict the efficacy, safety and tolerability of GLP-1 therapies. Using Ovation’s longitudinal clinical and… Read More
What if you could see diseases like Parkinson’s coming years before symptoms appear? In this webinar, hosted by DDW and supported by Standard BioTools, Benoit Lehallier, PhD, Senior Director, Data Science at Alkahest will share how SomaScan Technology, alongside complementary proteomic platforms, uncovers signals that predict disease risk… Read More
